MX9700552A - Conjugados de vitamina b12 y proteinas. - Google Patents

Conjugados de vitamina b12 y proteinas.

Info

Publication number
MX9700552A
MX9700552A MX9700552A MX9700552A MX9700552A MX 9700552 A MX9700552 A MX 9700552A MX 9700552 A MX9700552 A MX 9700552A MX 9700552 A MX9700552 A MX 9700552A MX 9700552 A MX9700552 A MX 9700552A
Authority
MX
Mexico
Prior art keywords
vitamin
administration
conjugates
proteins
delivery
Prior art date
Application number
MX9700552A
Other languages
English (en)
Inventor
Alan David Habberfield
Olaf Boris Kinstler
Colin Geoffrey Pitt
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX9700552A publication Critical patent/MX9700552A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid

Landscapes

  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen las proteínas terapéuticamente utiles que están conjugadas a la vitamina B12 mediante enlace covalente en el sitio del carboxilo primario de la porcion de ribosa. Los conjugados resultantes son biologicamente activos y pueden ser formulados en composiciones farmacéuticas apropiadas para la distribucion de diversas rutas de administracion, preferentemente oral. La captacion en el intestino después de la distribucion oral es además mejorada por la co-administracion del factor intrínseco purificado.
MX9700552A 1994-07-29 1995-07-28 Conjugados de vitamina b12 y proteinas. MX9700552A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/282,384 US5574018A (en) 1994-07-29 1994-07-29 Conjugates of vitamin B12 and proteins
PCT/US1995/009477 WO1996004016A1 (en) 1994-07-29 1995-07-28 Conjugates of vitamin b12 and proteins

Publications (1)

Publication Number Publication Date
MX9700552A true MX9700552A (es) 1997-05-31

Family

ID=23081275

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9700552A MX9700552A (es) 1994-07-29 1995-07-28 Conjugados de vitamina b12 y proteinas.

Country Status (6)

Country Link
US (1) US5574018A (es)
EP (1) EP0774976A1 (es)
JP (1) JPH09508141A (es)
CA (1) CA2195566A1 (es)
MX (1) MX9700552A (es)
WO (1) WO1996004016A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69528523T2 (de) * 1994-04-08 2003-06-12 Receptagen Corp Rezeptor modulierendes mitteln und entsprechendes verfahren
US5869465A (en) * 1994-04-08 1999-02-09 Receptagen Corporation Methods of receptor modulation and uses therefor
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US5739313A (en) 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
PT1007533E (pt) 1996-08-27 2005-09-30 Univ Utah Res Found Bioconjugados e administracao de agentes bioactivos
AUPP405098A0 (en) * 1998-06-12 1998-07-02 Access Pharmaceuticals Australia Pty Limited Novel methods of preparation of vitamin b12 derivatives suitable for conjugation to pharmaceuticals
AU2003204343B2 (en) * 1998-06-12 2007-03-15 Access Pharmaceuticals Australia Pty Limited Vitamin B12 derivatives and methods for their preparation
US20010008627A1 (en) 1999-01-22 2001-07-19 Soll David R. Hiv-encoded chemoattractant
US6806363B1 (en) * 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
JP2003512338A (ja) * 1999-10-15 2003-04-02 メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ 造影剤および抗腫瘍薬として有用なコバラミン結合体
US7591995B2 (en) 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
MXPA02003772A (es) 1999-10-15 2005-04-28 Mayo Foundation Conjugados de cobalamina, utiles como agentes para obtencion de imagen y como agentes terapeuticos.
AU781506B2 (en) 2000-02-03 2005-05-26 Eisai R&D Management Co., Ltd. Integrin expression inhibitors
US20020042394A1 (en) * 2000-05-31 2002-04-11 Hogenkamp Henricus P.C. Cobalamin compounds useful as antibiotic agents and as imaging agents
AU6972901A (en) * 2000-05-31 2001-12-11 Mayo Foundation Cobalamin compounds useful as cardiovascular agents and as imaging agents
WO2002055530A2 (en) * 2000-10-25 2002-07-18 Mayo Foundation Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
EP1754712A3 (en) * 2000-10-25 2009-01-14 Mayo Foundation For Medical Education And Research Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
WO2002067995A1 (en) * 2001-02-26 2002-09-06 Council Of Scientific And Industrial Research Carrier systems comprising vitamin b12 - biodegradable micro particulate conju gates for peroral delivery of drugs, peptides/proteins and vaccines
US20050175585A1 (en) * 2001-06-11 2005-08-11 Transition Therapeutics Inc. Combination therapies using vitamin B12 and interferon for treatment of viral proliferative and inflammatory disesases
JP2005506957A (ja) 2001-06-11 2005-03-10 トランジション・セラピューティックス・インコーポレーテッド ウイルス性、増殖性および炎症性の疾患の治療のためにビタミンｂ１２およびインターフェロンを用いた複合治療
WO2003000010A2 (en) * 2001-06-20 2003-01-03 Mayo Foundation For Medical Education And Research Adenosyl-cobalamin fortified compositions
US20060074034A1 (en) * 2001-09-17 2006-04-06 Collins Douglas A Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
EP1435973A4 (en) * 2001-09-28 2007-05-02 Mayo Foundation SIMULTANEOUS ADMINISTRATION OF A TRANSPORT PROTEIN WITH CONJUGATED COBALAMINE FOR THE DISTRIBUTION OF MEDICINAL PRODUCTS
WO2003030929A1 (en) * 2001-10-05 2003-04-17 Transition Therapeutics Inc. Combination therapies using methyl donors or methyl donor enhancers and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
MXPA04008068A (es) * 2002-02-20 2004-11-26 Lilly Co Eli Metodo para administrar moleculas de glp-1.
KR100440725B1 (ko) * 2002-06-20 2004-07-15 주식회사 그린진 바이오텍 비생물성 스트레스에 대한 단자엽 식물의 내성을증가시키는 방법
US20040047917A1 (en) * 2002-09-06 2004-03-11 Stephen Wilson Drug delivery and targeting with vitamin B12 conjugates
DK1592457T3 (da) * 2003-01-27 2012-10-22 Endocyte Inc Folat-vinblastin-konjugat som lægemiddel
US7232805B2 (en) * 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
US20110092416A1 (en) * 2007-03-05 2011-04-21 Robert Patrick Doyle Vitamine B12 - Peptide Conjugates for Oral Delivery
EP2131855A2 (en) * 2007-03-05 2009-12-16 Syracuse University A conjugate of insulin and vitamin b12 for oral delivery
AU2008268432B2 (en) 2007-06-25 2015-01-15 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US20100330161A1 (en) * 2009-06-29 2010-12-30 Syracuse University Technology Transfer And Industrial Development Office Oral delivery of tetanus toxoid
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
CN103501821A (zh) 2011-03-08 2014-01-08 艾克塞斯制药公司 用于递送活性剂穿过生物膜的靶向纳米载体系统
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
KR102238317B1 (ko) 2012-05-17 2021-04-12 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어
US20160199500A1 (en) * 2013-08-22 2016-07-14 Syracuse University Compositions comprising vitamin b12 and intrinsic factor and methods of use thereof
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US10716827B2 (en) 2015-05-20 2020-07-21 Syracuse University Compositions and methods for enhancing peptide stability against protease digestion
WO2016187499A1 (en) * 2015-05-20 2016-11-24 Syracuse University Improved glycemic control using intrinsic factor bound to a vitamin b12 conjugate of a glucagon-like peptide- 1 receptor agonist
EP3432870A4 (en) * 2016-03-22 2019-11-20 Balchem Corporation COMPOSITIONS WITH CHOLIN
GB202018713D0 (en) 2020-11-27 2021-01-13 Quadram Inst Bioscience Methods and compositions utilising vitamin b12 binding

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3981863A (en) * 1975-02-25 1976-09-21 Micromedic Diagonistics, Inc. Cyanocobalamin derivatives
NZ217821A (en) * 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
AU5356490A (en) * 1989-04-03 1990-11-05 Purdue Research Foundation Method for enhancing transmembrane transport of exogenous molecules
CA2084194C (en) * 1991-04-02 2003-05-20 Gregory John Russell-Jones Oral delivery systems for microparticles
SG50426A1 (en) * 1993-05-20 1998-07-20 Biotech Australia Pty Ltd Lhrh antagonists
US5449720A (en) * 1993-05-24 1995-09-12 Biotech Australia Pty Limited Amplification of the VB12 uptake system using polymers
US5548064A (en) * 1993-05-24 1996-08-20 Biotech Australia Pty Limited Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions

Also Published As

Publication number Publication date
WO1996004016A1 (en) 1996-02-15
AU683581B2 (en) 1997-11-13
JPH09508141A (ja) 1997-08-19
US5574018A (en) 1996-11-12
CA2195566A1 (en) 1996-02-15
AU3201595A (en) 1996-03-04
EP0774976A1 (en) 1997-05-28

Similar Documents

Publication Publication Date Title
MX9700552A (es) Conjugados de vitamina b12 y proteinas.
DE69925830D1 (de) Peg-lhrh analog konjugate
NO981436D0 (no) Farmasöytiske angiostatiske dipeptidsammensetninger og anvendelse derav
GEP20053473B (en) High Potency Dihydroergotamine Compositions
TR200002299T2 (tr) Epotilon kompozisyonları.
AR008378A1 (es) Conjudados de interferon
MX9700081A (es) Composiciones farmaceuticas de tacrina.
PH24313A (en) Emulsion composition for administration of sparingly water soluble ionizable hydrophobic drugs
UA66857C2 (uk) КОН'ЮГАТ ПОЛІОЛ-<font face="Symbol">b</font>-ІНТЕРФЕРОН, СПОСІБ ОДЕРЖАННЯ КОН'ЮГАТУ ПОЛІОЛ-<font face="Symbol">b</font>-ІНТЕРФЕРОН ТА СПОСІБ ЛІКУВАННЯ ІНФЕКЦІЙНИХ ХВОРОБ, ПУХЛИН І АУТОІМУННИХ І ЗАПАЛЬНИХ ЗАХВОРЮВАНЬ
FI890599A0 (fi) Antracyklin-immunokonjugater med ny linker och foerfarande foer deras producering.
HUP0100507A2 (hu) Polietilén-glikol-GRF konjugátumok, eljárás azok helyspecifikus előállítására, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
HRP20020787B1 (en) Method of treatment using ligand-immunogen conjugates
MY118371A (en) Tetrahydrolipstatin containing compositions
AU2874099A (en) Low molecular weight compounds administered together with anti-cancer agents to treat cancer and pharmaceutical compositions thereof
FR2762843B1 (fr) Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
ATE198834T1 (de) Konjugate bestehend aus polysaccharid und protein
HUT75513A (en) Taxane class derivative based pharmaceutical compositions and their preparation
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
HUP0302635A2 (hu) Valpronsav foszfolipidszármazékai és ezek keveréke
MY113203A (en) Lyophilizate of lipid complex of water insoluble camptothecins
BR9611571B1 (pt) composiÇço farmacÊutica estÁvel, kit para administraÇço de ngf e produto medicinal.
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
TR199900770T2 (xx) Nazal poliplerin tedavisinde bir H+, K+-ATPase'�n kullan�lmas�.
CA2403721A1 (en) Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor
BG103435A (en) Lamivudin- and zidovudin-containing pharmaceutical compositions